{
    "organizations": [],
    "uuid": "6419a2afeb98eab5a147f1460529468a1553ada7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-teva-pharm-comments-from-conferenc/brief-teva-pharm-comments-from-conference-call-post-q1-results-idUSJ7N1NL00F",
    "ord_in_thread": 0,
    "title": "BRIEF-Teva Pharm comments from conference call post-Q1 results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3, 2018 / 1:09 PM / Updated 7 minutes ago BRIEF-Teva Pharm comments from conference call post-Q1 results Reuters Staff 1 Min Read\nMay 3 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA PHARM CEO SCHULTZ: STILL EXPECT TO SELL $4 BILLION WORTH OF GENERIC DRUGS IN U.S. IN 2018\n* TEVA PHARM CEO SCHULTZ: MIGRAINE DRUG LIKELY TO BE APPROVED FOR QUARTERLY DOSAGE\n* TEVA PHARM CEO SCHULTZ: NO PLANS TO ISSUE NEW EQUITY, NO PLANS FOR M&A ACTIVITY\n* TEVA PHARM: DEVELOPING PEN DEVICE FOR MIGRAINE DRUG BUT NO SPECIFIC DATE FOR LAUNCH\n* TEVA PHARM CFO: EXPECTS TO PAY DOWN ANOTHER $1.3-$1.5 BILLION OF DEBT IN 2018\n* TEVA PHARM: NO EXPECTATION FOR ANOTHER 40 MG GENERIC VERSION OF COPAXONE IN 2018 Further company coverage: (Reporting by Steven Scheer and Tova Cohen)",
    "published": "2018-05-03T21:09:00.000+03:00",
    "crawled": "2018-05-03T16:18:49.027+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharm",
        "comment",
        "conference",
        "call",
        "result",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "teva",
        "pharm",
        "ceo",
        "schultz",
        "still",
        "expect",
        "sell",
        "billion",
        "worth",
        "generic",
        "drug",
        "teva",
        "pharm",
        "ceo",
        "schultz",
        "migraine",
        "drug",
        "likely",
        "approved",
        "quarterly",
        "dosage",
        "teva",
        "pharm",
        "ceo",
        "schultz",
        "plan",
        "issue",
        "new",
        "equity",
        "plan",
        "activity",
        "teva",
        "pharm",
        "developing",
        "pen",
        "device",
        "migraine",
        "drug",
        "specific",
        "date",
        "launch",
        "teva",
        "pharm",
        "cfo",
        "expects",
        "pay",
        "another",
        "billion",
        "debt",
        "teva",
        "pharm",
        "expectation",
        "another",
        "mg",
        "generic",
        "version",
        "copaxone",
        "company",
        "coverage",
        "reporting",
        "steven",
        "scheer",
        "tova",
        "cohen"
    ]
}